drugset / Trial / NCT01091051

Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis

NCT01091051

Phase 3 Terminated 33 enrolled Innovaderm Research Inc. Janssen-Ortho LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will provide data on sasety and efficacy of Ustekinumab in patients suffering from Palmo-Plantar Pustular Psoriasis (PPPP) or Palmo-Plantar Pustulosis(PPP)

Timeline

Start
2010-03
Primary completion
2011-08
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ustekinumab Monoclonal antibody 45 mg Subcutaneous
Comparator Ustekinumab Monoclonal antibody 90 mg Subcutaneous